The outcomes: Approved on first submission: 34% (286 requests) Denied, then approved on appeal with additional documentation: 29% (244 requests) Denied, appeal denied, patient switched to compounded semaglutide: 31% (260 requests) Denied, patient abandoned treatment: 6% (50 requests) The pattern that emerges: patients who succeed in getting Wegovy covered through Express Scripts are patients whose providers submitted complete documentation on the first attempt
On one hand, FDA-approved obesity medications already exist (Wegovy, Zepbound, Foundayo), which historically has made priority review less likely for later entrants
Inject slowly and steadily : Rapid injection can cause more tissue disruption
The second speaker was David McGarel, CIO of First Trust
Tirzepatide side effects Tirzepatide side effects center almost entirely on the gastrointestinal system
The catheter is removed and pressure is held over this area for approximately 15 minutes